(MedPage Today) — The FDA on Thursday approved the immunotherapy zopapogene imadenovec (Papzimeos) for adults with recurrent respiratory papillomatosis (RRP), a rare chronic disease driven by persistent human papillomavirus (HPV) infection.
This…
Source link : https://www.medpagetoday.com/pulmonology/generalpulmonary/117030
Author :
Publish date : 2025-08-15 21:05:00
Copyright for syndicated content belongs to the linked Source.